Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Norovirus GII.3 major capsid protein (VP1) is the essential structural unit of the viral capsid, responsible for both protecting the viral RNA genome and mediating host cell recognition (UniProt: P03310). It is composed of two main domains: the S (shell) domain, which forms the internal scaffold, and the P (protruding) domain, which extends outward and interacts with host receptors (PubMed: 24965445). Specifically, the P2 subdomain within the P domain contains the binding pockets for histo-blood group antigens (HBGAs), which are the primary attachment factors for noroviruses (PubMed: 25589522). GII.3 is a significant genotype frequently associated with endemic and epidemic outbreaks of acute gastroenteritis, particularly in pediatric populations (PubMed: 30135128). Because it is the most immunogenic and exposed viral component, VP1 is the primary target for neutralizing antibodies and the central focus of vaccine strategies, such as virus-like particles (VLPs) and adenovirus-vectored vaccines (ClinicalTrials.gov: NCT04854746). Current drug development efforts also explore small-molecule inhibitors designed to occupy the HBGA-binding site, thereby preventing viral entry and infection. Understanding the structural evolution of the GII.3 capsid is vital for addressing the challenges of antigenic drift and ensuring broad-spectrum protection against emerging norovirus strains.
Neutralization of viral particles and competitive inhibition of attachment to host histo-blood group antigens (HBGAs).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Norovirus GII.3 major capsid protein (VP1) (VP1).